Hereby, we aimed to predict response to treatment in HER2‐negative, early‐stage breast cancer patients treated in the Dutch Breast Cancer Research Group (BOOG) phase III, randomized, multicenter DIRECT23 and NEOZOTAC trials.24 This evidence concerns the gene ERBB2 and breast carcinoma.